What Was Merck Thinking Buying Idenix Pharmaceuticals?

It's been a rocky road for hepatitis C drugmaker Idenix Pharmaceuticals (NASDAQ: IDIX  ) , but investors are smiling after Merck (NYSE: MRK  ) announced on Monday that it's buying the biotech for $3.85 billion, more than a 230% premium on Friday's closing price. Even investors who bought at the previous top a few years ago when investors had high hopes that every hepatitis C biotech was going to get bought still had a profitable ending.

Fellow hepatitis C drugmaker Achillion (NASDAQ: ACHN  ) was up big yesterday, with investors hoping that it'll get bought out as well, but investors should be careful here; there are diminishing potential returns as each hepatitis C drugmaker gets picked off. With Merck now owning Idenix Pharmaceuticals, there's one less company that might want to purchase Achillion.

Gilead Sciences (NASDAQ: GILD  ) traded down, presumably because investors are worried that Merck will become a stronger competitor with Idenix's assets, but there is upside for Gilead Sciences' investors: Merck's purchase is a sign that the pharma thinks there will be plenty of patients a few years from now, when Idenix Pharmaceuticals' drugs could make it to market.

Watch the following video for thoughts on the deal from senior biotech specialist Brian Orelli and health-care analyst David Williamson, including the potential wildcard: patents.

Not a biotech, but this stock has multi-bagger potential
Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2988209, ~/Articles/ArticleHandler.aspx, 8/29/2015 8:59:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
ACHN $7.76 Up +0.25 +3.33%
GILD $107.78 Down -0.21 -0.19%
Gilead Sciences CAPS Rating: *****
IDIX $0.00 Down +0.00 +0.00%
Idenix Pharmaceuti… CAPS Rating: **
MRK $55.37 Up +0.42 +0.76%
Merck & Co., Inc. CAPS Rating: ****